Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 145Parkinson Disease 4, Autosomal Dominant Lewy Body 120Melanoma 84Squamous Cell Carcinoma of Head and Neck 56Neoplasms 44Breast Neoplasms 41Stomach Neoplasms 39Colorectal Neoplasms 38Triple Negative Breast Neoplasms 37Neoplasm Metastasis 36Carcinoma, Renal Cell 36Ovarian Neoplasms 30Lung Neoplasms 30Head and Neck Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Transitional Cell 26Carcinoma, Hepatocellular 26Pancreatic Neoplasms 23Esophageal Neoplasms 20Endometrial Neoplasms 16Recurrence 15Prostatic Neoplasms 15Multiple Myeloma 15Fallopian Tube Neoplasms 15Carcinoma 14Sarcoma 13Lymphoma, Large B-Cell, Diffuse 13Small Cell Lung Carcinoma 12Lymphoma, Follicular 12Lymphoma, Non-Hodgkin 11

Interventions

Nivolumab 4pertuzumab 2pembrolizumab 2durvalumab 2Paclitaxel 2Docetaxel 2Capecitabine 2ulocuplumab 1tremelimumab 1tazarotene 1talazoparib 1romiplostim 1pexidartinib 1pamiparib 1onartuzumab 1magrolimab 1entrectinib 1cobimetinib 1atezolizumab 1Sunitinib 1Rifampin 1Ramucirumab 1Radiosurgery 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1Midazolam 1MK-4166 1LY3022855 1LY2510924 1LY-2157299 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Solid Tumor × pembrolizumab × Clear all
NCT03894540 2022-09-13

Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

Ipsen

Phase 1 Terminated
22 enrolled 27 charts
Other solid neoplasm

Solid Tumor

NCT02132754 2021-01-28

MK-4166-001

Merck Sharp & Dohme LLC

Phase 1 Completed
116 enrolled 61 charts
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡